Prostate Cancer News and reporting on prostate cancer. Oct 25, 2022 Pluvicto Sales Ramp up, Kisqali Gains Continue in Q3 for Novartis Premium Oct 21, 2022 PSMA, Tumor Metabolic Volume May Help Refine Pluvicto Use in Prostate Cancer, Study Suggests Premium Oct 20, 2022 Ayala Pharmaceuticals, Advaxis Announce Merger With Refocused Precision Oncology Pipeline Premium Oct 19, 2022 Blue Earth Diagnostics, Siemens Healthineers Partner on Prostate Cancer Theranostics, PET Imaging Oct 14, 2022 EMA's CHMP Recommends Novartis' Pluvicto for PSMA-Positive mCRPC Oct 7, 2022 Clarity Pharmaceuticals Begins Dosing Patients in Radiopharmaceutical Prostate Cancer Trial Oct 3, 2022 Clovis Oncology to File sNDA for Rubraca in BRCA1/2-Mutant Prostate Cancer Sep 29, 2022 New NIH-Funded Network Aims to Bring Precision to External Beam Radiation Treatment Premium Sep 27, 2022 Telix Pharmaceuticals Begins Phase II Trial of Radiolabeled Prostate Cancer Antibody Treatment Aug 2, 2022 MDxHealth Acquires Prostate Cancer Testing Business From Exact Sciences for up to $100M Jul 29, 2022 Sotio Biotech Begins Phase II Trial of IL-15-Targeted Candidate in Solid Tumors Jul 28, 2022 Merck's Keytruda Q2 Sales Grow 26 Percent; Firm Considers Future Impact of Medicare Price Setting Premium Jul 21, 2022 Convergent Therapeutics Banking on Radioantibody Approach for PSMA-Targeted mCRPC Treatment Premium Jul 20, 2022 Treatment-Resistant Prostate Cancer Clues Drawn From Circulating Tumor DNA Dynamics Jul 13, 2022 Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients Jun 16, 2022 Ratio Therapeutics Launches to Develop More Target-Specific, Less Toxic Radiopharmaceuticals Premium Jun 10, 2022 Telix Pharmaceuticals, RefleXion Medical to Develop Illuccix-Guided Radiotherapy for Prostate Cancer Jun 7, 2022 African American Prostate Cancer Patients Get More VUS, Fewer Actionable Results, Studies Show Jun 6, 2022 VISION Trial Sub-Studies Refine Pluvicto Benefit as Radiopharmaceutical Access Barriers Persist Premium Jun 6, 2022 Foundation Medicine, Arvinas Partner to Develop CDx For Prostate Cancer Drug Load More Breaking News Enhertu Shows Activity in Early-Stage HER2-Low Breast Cancer Patients in Study Reported at SABCS Dragonfly Therapeutics Begins Phase II Trial of HER2-Targeted NK-Cell Engager Touchlight to Provide DNA Vector for Odimma Therapeutics' Personalized Neoantigen Vaccine Trial FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy Caris Life Sciences, Hummingbird Bioscience Partner on Anti-HER3 Therapy Advancement Akeso, Summit Therapeutics Ink $5B Licensing Deal for PD-1/VEGF Bispecific Antibody
